FY2024 Earnings Estimate for TSE:ONC Issued By HC Wainwright

Oncolytics Biotech Inc. (TSE:ONC) – Analysts at HC Wainwright reduced their FY2024 EPS estimates for Oncolytics Biotech in a note issued to investors on Wednesday, November 13th. HC Wainwright analyst P. Trucchio now anticipates that the company will post earnings of ($0.41) per share for the year, down from their previous estimate of ($0.39). The consensus estimate for Oncolytics Biotech’s current full-year earnings is ($0.41) per share. HC Wainwright also issued estimates for Oncolytics Biotech’s Q3 2025 earnings at ($0.10) EPS.

Separately, Raymond James upgraded shares of Oncolytics Biotech to a “moderate buy” rating in a research note on Thursday, November 14th.

Oncolytics Biotech Trading Up 0.7 %

TSE:ONC opened at C$1.39 on Monday. Oncolytics Biotech has a 12 month low of C$1.15 and a 12 month high of C$2.32. The firm has a fifty day simple moving average of C$1.50 and a 200-day simple moving average of C$1.45. The company has a current ratio of 4.99, a quick ratio of 8.86 and a debt-to-equity ratio of 6.09. The company has a market capitalization of C$106.84 million, a P/E ratio of -3.63 and a beta of 1.35.

About Oncolytics Biotech

Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.